Events

May
22
Wed
Microbiome Movement — Maternal & Infant Health
May 22 – May 24 all-day
Microbiome Movement — Maternal & Infant Health

The 1st Microbiome Movement – Maternal & Infant Health Summit brings together large pharma, biotech companies, research institutes, and technology experts to harness the causality of maternal-infant microbiome and translate it into therapeutic, nutritional, and preventative solutions for early life health outcomes. Key topics include discovering causal relationships between the maternal-infant microbiome and disease onset and exploring different therapeutic products that restore the infant microbiome, as well as treat and prevent disease. Attendess can expect to learn about study design for investigation of the microbiome in maternal and pediatric settings; the role of the maternal microbiome in preterm birth and infant health outcomes; how to integrate omics data with novel preclinical modelling to generate clinically meaningful results; regulatory processes for IND-approved products targeting maternal and infant populations; and public health, economic, and educational considerations for commercializing microbiome- based products for mothers and infants. This new conference promises to unlock the full potential of preventative, therapeutic and nutritional solutions in the key window of opportunity of the first 1000 days of life.

May
31
Fri
ASCO Annual Meeting
May 31 – Jun 4 all-day

ASCO offers a robust program designed to teach, engage, and bring the oncology field together. In addition to presenting the latest research in cancer care, the program will feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Learn more about the program offerings this year, including featured sessions and pre-Annual Meeting Seminars. The Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. The conference program includes a wide variety of sessions: educational sessions, plenary session, meet the professor, clinical science symposia, and poster presentations session. Pre-meeting seminars will be from 1:00 p.m. to 5:00 p.m. on May 30, and 7:30 a.m. to 11:00 a.m. on May 31. When not attending cutting-edge presentations, attendees can visit the exhibit hall with more than 440 exhibiting companies.

Jun
17
Mon
Biomarker World Congress
Jun 17 – Jun 19 all-day

Cambridge Healthtec Institute’s Biomarker World Congress is now a part of World Pharma Week. Now in its 15th year, Congress is the longest-running event dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines. With the promising developments in immuno-oncology, significant biomarker R&D has shifted to discovery and development of predictive biomarkers for immunotherapy patient stratification, using biomarker or mechanism data to choose rational combination immunotherapy, and applying immune profiling to predict response to immunotherapy. Advances in clinical and translational biomarkers will also be covered, including patient selection and predicting response to therapy, liquid biopsy and cell free DNA, companion diagnostics and personalized medicine, biomarker assay development and validation, and biomarker-based clinical trials.

Aug
20
Tue
Next Generation Dx Summit
Aug 20 – Aug 22 all-day

Next Generation Dx Summit attracts more than 800 international diagnostic professionals for the latest develops in the industry ranging from biomarker identification and clinical diagnostic development to precision medicine and business strategy. Celebrating its 11th year, the conference spans point-of-care testing, infectious disease diagnostics, companion diagnostics, liquid biopsy, digital pathology and AI, immuno-oncology, insurance coverage and reimbursement, and commercialization of diagnostics. Short course topics during the conference include technologies, applications and commercialization of POC Dx, tumor mutation burden, and data-driven process development in the clinical laboratory, among others.